Core Viewpoint - Recently, Hisco (002653) received approval from the Shenzhen Stock Exchange's Listing Review Center for its application to issue shares to specific investors [1] Group 1: Share Issuance Details - Hisco plans to issue no more than 70 million shares, which does not exceed 30% of the total share capital prior to this issuance [4] - The total amount of funds to be raised from this issuance is capped at 1,245.2567 million yuan, which will be used for new drug research and development projects and to supplement working capital [4] Group 2: Fund Allocation - The investment amount for the new drug research project is 965.2567 million yuan, while 280 million yuan will be allocated to supplement working capital [5] - The total amount of funds raised will be 1,245.2567 million yuan [5] Group 3: Strategic Importance - The company is currently in a critical phase of transitioning to innovative drugs, maintaining a high level of R&D investment, with R&D expenditures as a percentage of revenue reaching 31.87%, 26.09%, and 26.90% for the years 2022 to 2024 respectively [6] - The company has seen a continuous expansion in market share for its key products, with innovative drugs such as the injection of环泊酚 (Sishuning), the capsule of苯磺酸克利加巴林 (Simeining), and others being included in the medical insurance directory [6] - The implementation of this fundraising project is expected to accelerate the R&D process of innovative drugs, expanding the depth and breadth of the company's product pipeline, thereby laying a solid foundation for the commercialization of more products [6]

Core Viewpoint - The company reported a revenue of 3.721 billion yuan for 2024, marking a year-on-year increase of 10.92%, while net profit attributable to shareholders reached 395 million yuan, up 34% [1] Group 1: Financial Performance - The company's revenue for 2024 was 3.721 billion yuan, reflecting a 10.92% increase compared to the previous year [1] - Net profit attributable to shareholders was 395 million yuan, representing a 34% year-on-year growth [1] - The company's non-recurring net profit decreased by 45.4% to 132 million yuan, with a loss reported in the fourth quarter [1] Group 2: Factors Affecting Performance - The decline in non-recurring net profit was primarily due to increased investment in innovative drug research and development, with R&D expenses amounting to 62.414 million yuan, an increase of 10.746 million yuan year-on-year [1] - Asset impairment losses for the year totaled 82.39 million yuan, up 7.226 million yuan from the previous year, mainly due to a 53.45 million yuan impairment loss from the termination of the riluzole project [1] - In the fourth quarter, R&D expenses were particularly high at 24.616 million yuan, accounting for approximately 39% of the annual R&D expenses [1] Group 3: Government Support and Market Reaction - The company received significant government subsidies amounting to 189 million yuan, linked to local policy execution [2] - On April 11, the company's stock price hit a historical high, closing at a limit-up, but subsequently experienced a decline of over 5% on April 14 [2] - As of the latest report, the stock price was 45.82 yuan per share, reflecting a decrease of 3.44% [2]